iii

Tejas Networks emerges as a leading supplier of IP Routing products across the country for BharatNet Phase III packages

BENGALURU, India, Dec. 11, 2025 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that the company has been awarded…

2 days ago

Ashika Investment Managers launches Ashika Mid & Small Cap Fund, an open-ended Category III AIF

MUMBAI, India, Dec. 9, 2025 /PRNewswire/ -- Ashika Investment Managers Pvt. Ltd. has received node from SEBI for launch of…

4 days ago

Carl H. Sharperson III Joins MATTER Board of Directors

December 03, 2025 10:00 ET  | Source: MATTER MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based…

1 week ago

Sustainable Markets Initiative Hosts Landmark Private Capital Mobilization Convening in London, with a report back session attended by His Majesty King Charles III

LONDON, Dec. 2, 2025 /PRNewswire/ -- Yesterday, the Sustainable Markets Initiative hosted a gathering of Heads of States and Government,…

2 weeks ago

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…

2 weeks ago

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…

2 months ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…

3 months ago

Delska’s New 10MW Data Center in Latvia Achieves Tier III Design Certification

RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming facility, EU North Riga LV DC1, has been…

4 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…

4 months ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…

4 months ago